Letrozol Teva-Ratiopharm (Letrozole)

Letrozole works by selectively inhibiting the aromatase enzyme, which converts androgens into estrogens in peripheral tissues. By blocking this conversion, circulating estrogen levels fall, depriving estrogen‑dependent tumor cells of the growth signal they need, which slows tumor proliferation.

The specific dose of letrozole is determined by the prescribing physician based on the patient’s clinical condition, treatment setting and regulatory guidelines. Healthcare providers decide the appropriate strength, frequency and duration of therapy for each individual.

Letrozole is contraindicated in pregnancy because it can interfere with fetal development by reducing estrogen levels. It is also not recommended for breastfeeding mothers, as it may pass into breast milk and affect the infant. Women of child‑bearing potential should use effective contraception during treatment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Letrozol Teva‑Ratiopharm. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Letrozole, anastrozole and exemestane are the three main aromatase inhibitors used in postmenopausal breast cancer. Letrozole is often considered the most potent inhibitor of estrogen synthesis, offering slightly higher efficacy in some studies, while having a comparable safety profile. Choice of agent depends on physician preference, patient tolerance and specific clinical scenarios.

Letrozol Teva‑Ratiopharm should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight and excessive heat to maintain its stability and potency throughout its shelf life.

Letrozole is taken orally, usually as a single tablet swallowed with water. It is administered once daily, preferably at the same time each day, and can be taken with or without food. Patients should follow the dosing schedule prescribed by their healthcare professional.

Serious adverse events associated with letrozole include severe liver injury, osteoporosis‑related fractures, and rare allergic reactions such as anaphylaxis. Patients should be monitored for signs of hepatic dysfunction, bone loss, or any sudden allergic symptoms and report them promptly to their physician.

Letrozole is contraindicated in premenopausal women, pregnant or nursing individuals, and patients with known hypersensitivity to letrozole or any component of the formulation. Caution is also advised for patients with severe liver impairment or uncontrolled cardiovascular disease, and it should be avoided in those taking strong CYP3A4 inducers without medical supervision.